Tag: clopidogrel

1. In this modern population of Canadian patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), the rates of major adverse cardiovascular events (MACE) at 1 year follow-up were the same in groups treated with ticagrelor or clopidogrel. Ticagrelor was linked with a higher risk of...
1. In this pre-specified ancillary study of a randomized control trial, ticagrelor alone after one month was found non-inferior, but not superior, to dual antiplatelet therapy in preventing ischemic events after drug eluting coronary stenting. 2. Ticagrelor did not decrease bleeding risk compared with dual antiplatelet therapy. Evidence Rating Level: 2...
While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of therapy remains controversial. American and European guidelines recommend DAPT for a minimum of 12 months for acute coronary syndrome (ACS), and at least 6 months in stable...
The current standard therapy following percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor, followed by aspirin (ASA) monotherapy. P2Y12 inhibitor monotherapy has recently been suggested as an alternative to DAPT, with studies showing reduced risk of subsequent ischemic...
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of...
1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for patients who had suffered a myocardial infarction (MI). 2. Medication vouchers were not associated with reduced major adverse cardiovascular events (MACE) in these patients. Evidence Rating Level: 1 (Excellent)       Study Rundown: Antiplatelet therapy,...
1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for patients who had suffered a myocardial infarction (MI). 2. Medication vouchers were not associated with reduced major adverse cardiovascular events (MACE) in these patients. Evidence Rating Level: 1 (Excellent)       Study Rundown:...
1. Use of ticagrelor resulted in similar rates of major bleeding compared to clopidogrel in patients with ST elevation myocardial infarction treated with thrombolysis. Evidence Rating Level: 2 (Good) Study Rundown: Antiplatelet therapy is a major component of management of acute myocardial infarction. Ticagrelor results in greater and more rapid P2Y12...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants The novel oral anticoagulants (NOAC) are an emerging hot topic in medicine given their cost-effectiveness and monitoring preference compared to the traditional vitamin...
Image: PD 1. Prasugrel was more effective than clopidogrel in reducing the incidence of recurrent myocardial infarction in patients presenting with acute coronary syndrome, though there was no difference in mortality between the two groups 2. Patients treated with prasugrel had a significantly higher incidence of fatal major bleeding compared to...